Brain Cancer (Treatment)

Gliadel Receives FDA Clearance To Treat Cancer

Published in Cancer Weekly, October 7th, 1996

Rhone-Poulenc Rorer Inc. (RPR), Collegeville, Pennsylvania, and Guilford Pharmaceuticals Inc., Baltimore, Maryland, announced that Gliadel Wafer (polifeprosan 20 with carmustine implant) has received clearance from the U.S. Food and Drug Administration (FDA) for use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (GBM) for whom surgical resection is indicated.

Gliadel is a brain cancer treatment to deliver chemotherapy directly to the tumor site. GBM is one of the most rapidly progressive and universally fatal of all cancers. There are approximately 20,000 primary brain tumors diagnosed in the United States each year and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry